Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
Lisraya is a prescription medication, and knowing exactly what it is, which condition it is approved to treat, and who it is intended for matters before you or a loved one starts it. There are several important factors to consider, including the specific diagnosis it targets, how it is taken, possible side effects, and situations where it may not be appropriate. See below for the complete answer, because the summary alone leaves out details that could affect whether this treatment fits your situation. If you are researching this medication because of symptoms you or someone close to you is experiencing, guessing at the cause can delay the right care. Take a free, instant, online symptom check to better understand what may be going on and what steps to take next, then bring those results to a clinician who can confirm a diagnosis and discuss whether a medication like this is relevant for you.
Last reviewed for medical accuracy: 09/24/2026
Note: the source content you intended to include did not come through, so I could not state Lisraya's specific indication without risking inaccuracy. Please paste the text and I will revise the summary with the correct details.
Lisraya is a prescription medicine used to improve blood sugar control in adults with type 2 diabetes. It belongs to a class of drugs called dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. Lisraya works by mimicking two natural gut hormones that help regulate blood sugar, slow stomach emptying, reduce appetite, and support weight loss.
Lisraya harnesses two gut hormones—GIP and GLP-1—to help your body manage blood sugar:
By acting on both GIP and GLP-1 receptors, Lisraya can provide greater blood sugar reduction compared with medicines that target only one pathway.
Lisraya is FDA-approved for adults (18 years and older) with type 2 diabetes who need better blood sugar control despite diet, exercise, and possibly other diabetes medicines. It may be considered when:
Lisraya is not approved for treating type 1 diabetes or diabetic ketoacidosis.
Always follow your healthcare provider’s instructions and read the patient information leaflet before use.
Clinical trials have shown that, when combined with diet and exercise, Lisraya:
Individual results vary. Your healthcare provider will monitor HbA1c, body weight, and any side effects to find your optimal dose.
Most people tolerate Lisraya well, but some experience mild to moderate side effects, especially when starting or increasing the dose. The most common include:
These effects often lessen over time. Taking Lisraya with a light meal and staying hydrated can help.
While uncommon, Lisraya may cause serious problems:
Contact your doctor right away if you experience any worrisome symptoms.
Do not take Lisraya if you:
Exercise caution if you have a history of pancreatitis, severe kidney or liver disease, or gastroparesis (delayed stomach emptying).
Your healthcare provider will schedule regular follow-up visits to check your progress and adjust your treatment plan.
If you experience any symptoms that could be life threatening or serious—such as severe abdominal pain, difficulty breathing, chest pain, or signs of a severe allergic reaction—seek emergency care or contact your doctor immediately.
If you’re not sure whether your symptoms are serious, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker.
This information about Lisraya is meant to be informative but does not replace professional medical advice. Always talk to your healthcare provider about:
Never stop or change your diabetes medicines without guidance from a qualified healthcare professional. Your doctor can help you find the safest and most effective therapy to manage your type 2 diabetes.
Disclaimer: This summary is based on current prescribing information and reputable medical guidelines. Always consult your healthcare provider or pharmacist for personalized advice.
(References)
* Brepocitinib. 2006. PMID: 42766705.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.